Journal
JOURNAL OF NEURAL TRANSMISSION
Volume 117, Issue 6, Pages 737-746Publisher
SPRINGER WIEN
DOI: 10.1007/s00702-010-0401-z
Keywords
Parkinson's disease; 8-OxodG; Micronuclei L-DOPA; Dopamine
Categories
Funding
- IZKF Wuerzburg (Interdisciplinary Clinical Center of the University of Wuerzburg) [N5-1]
- German Excellence Initiative to the Graduate School of Life Sciences, University of Wuerzburg
Ask authors/readers for more resources
Parkinson's disease (PD) is a neurodegenerative movement disorder affecting about 2% of the human population in old age. l-3,4-Dihydroxyphenylalanine (l-DOPA) in combination with a peripheral aromatic amino acid decarboxylase inhibition has been the most frequently prescribed drug for alleviating symptoms of PD, but a potential contribution of l-DOPA therapy to further neurodegeneration via oxidative stress is still debated. We report that the specific oxidative stress biomarker 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) level in peripheral blood lymphocyte DNA was elevated to 8.1 +/- A 1.7 8-oxodG/10(6)dG in 17 chronically l-DOPA-treated PD patients, compared to 4.6 +/- A 1.2 8-oxodG/10(6)dG in 12 controls. However, the total antioxidative capacity of plasma was increased to 1113 +/- A 237 mu M in the PD patients compared to 941 +/- A 254 mu M in controls. The frequency of micronuclei, a subgroup of chromosomal aberrations, in peripheral blood lymphocytes was not elevated compared to healthy age-matched individuals. In vitro, in a cell-free assay, dopamine and its precursor l-DOPA exhibited antioxidative capacity. On the other hand, the 8-oxodG concentration in cultured PC 12 cells was enhanced after dopamine treatment. This elevation may be below a threshold for manifestation as chromosomal damage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available